A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
Public ClinicalTrials.gov record NCT03112603. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III Randomized Open-label Multi-center Study of Ruxolitinib vs. Best Available Therapy in Patients With Corticosteroid-refractory Chronic Graft vs Host Disease After Allogeneic Stem Cell Transplantation (REACH3)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the efficacy of ruxolitinib against best available therapy in participants with steroid-refractory chronic graft-versus-host disease (SR cGvHD).
Study identification
- NCT ID
- NCT03112603
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 330 participants
Conditions and interventions
Conditions
Interventions
- Ruxolitinib Drug
- Extracorporeal photopheresis (ECP) Drug
- Low-dose methotrexate (MTX) Drug
- Mycophenolate mofetil (MMF) Drug
- mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus) Drug
- Infliximab Drug
- Rituximab Drug
- Pentostatin Drug
- Imatinib Drug
- Ibrutinib Drug
Drug
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 29, 2017 (Actual)
- Primary completion
- May 8, 2020 (Actual)
- Completion
- Dec 15, 2022 (Actual)
- Last update posted
- Aug 12, 2025
2017 – 2022
United States locations
- U.S. sites
- 38
- U.S. states
- 21
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Incyte Investigative Site | Tucson | Arizona | 85724 | — |
| Incyte Investigative Site | Duarte | California | 31010 | — |
| Incyte Investigative Site | La Jolla | California | 92093-0987 | — |
| Incyte Investigative Site | Los Angeles | California | 90033 | — |
| Incyte Investigative Site | New Haven | Connecticut | 06510 | — |
| Incyte Investigative Site | Wilmington | Delaware | 19803 | — |
| Incyte Investigative Site | Gainesville | Florida | 32610 | — |
| Incyte Investigative Site | Tampa | Florida | 33612 | — |
| Incyte Investigative Site | Chicago | Illinois | 60611 | — |
| Incyte Investigative Site | Chicago | Illinois | 60612 | — |
| Incyte Investigative Site | Chicago | Illinois | 60637 | — |
| Incyte Investigative Site | Maywood | Illinois | 60153 | — |
| Incyte Investigative Site | Indianapolis | Indiana | 46237 | — |
| Incyte Investigative Site | Westwood | Kansas | 66205 | — |
| Incyte Investigative Site | Lexington | Kentucky | 40536 | — |
| Incyte Investigative Site | Boston | Massachusetts | 02114 | — |
| Incyte Investigative Site | Boston | Massachusetts | 02215 | — |
| Incyte Investigative Site | Omaha | Nebraska | 68198-7680 | — |
| Incyte Investigative Site | Hackensack | New Jersey | 07601 | — |
| Incyte Investigative Site | New York | New York | 10021 | — |
| Incyte Investigative Site | New York | New York | 10032 | — |
| Incyte Investigative Site | New York | New York | 11040 | — |
| Incyte Investigative Site | Chapel Hill | North Carolina | 27599 | — |
| Incyte Investigative Site | Durham | North Carolina | 27710 | — |
| Incyte Investigative Site | Winston-Salem | North Carolina | 27157 | — |
| Incyte Investigative Site | Cincinnati | Ohio | 45242 | — |
| Incyte Investigative Site | Cleveland | Ohio | 44106-5048 | — |
| Incyte Investigative Site | Cleveland | Ohio | 44195 | — |
| Incyte Investigative Site | Columbus | Ohio | 43210 | — |
| Incyte Investigative Site | Oklahoma City | Oklahoma | 73104 | — |
| Incyte Investigative Site | Philadelphia | Pennsylvania | 19104 | — |
| Incyte Investigative Site | Pittsburgh | Pennsylvania | 15224 | — |
| Incyte Investigative Site | Pittsburgh | Pennsylvania | 15232 | — |
| Incyte Investigative Site | Nashville | Tennessee | 37232 | — |
| Incyte Investigative Site | Dallas | Texas | 75390 | — |
| Incyte Investigative Site | Houston | Texas | 77030 | — |
| Incyte Investigative Site | Seattle | Washington | 98109 | — |
| Incyte Investigative Site | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 153 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03112603, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 12, 2025 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03112603 live on ClinicalTrials.gov.